Jiangsu Aidea Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Jiangsu Aidea Pharmaceutical Group Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- First human test: can a new drug called ADB116 be given safely? Results expected Dec 2026 (estimated)
- New HIV drug candidate targets resistant strains Results expected Jun 2027 (estimated)
-
Can a new pill tame HIV? early trial puts ACC017 to the test
Disease control CompletedThis early-stage trial is testing an experimental HIV drug called ACC017 in adults with HIV-1 who have never taken HIV medication. The study aims to see if the drug is safe, tolerable, and effective at lowering the amount of virus in the blood, both when used alone and when combi…
Phase 1/2 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new pill ACC017 be safely dosed? a trial seeks answers
Knowledge-focused CompletedThis early-stage trial is testing an experimental drug called ACC017 in healthy adults to see if it is safe and how the body processes it. Researchers are giving different single doses to small groups of volunteers, some receiving a placebo, to find a recommended dose for future …
Phase 1 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
One pill instead of three? HIV combo tablet put to the test
Knowledge-focused CompletedThis trial asks whether a single tablet combining three HIV medications (ACC017, emtricitabine, and tenofovir alafenamide) is absorbed by the body just as well as taking the same drugs separately. Healthy adult volunteers will receive both versions in a random order under fasting…
Phase 1 • Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC